Voyager Therapeutics, Inc

Industry

  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Synthesis Technologies, Production Processes
    • Large Molecule
      • Antibodies
    • Gene Therapy, Cell Therapy

Other Names/Subsidiaries

  • Third Rock Ventures, LLC
See more in Biomedtracker

Latest on Voyager Therapeutics, Inc

Scrip

Bayer’s BlueRock Moves Parkinson’s Cell Therapy into Phase III

 
• By Kevin Grogan

Founded eight years ago, Bayer subsidiary BlueRock Therapeutics is now putting the final touches to the late-stage program for bemdaneprocel, its closely watched investigational cell therapy for Parki

Scrip

PTC Gets $1bn From Novartis For Phase II Huntington’s Candidate

 
• By Joseph Haas

Novartis will bolster its neurodegeneration pipeline and specifically its Huntington’s disease portfolio in a license-and-collaboration deal with PTC Therapeutics announced on 2 December that analysts

Scrip

Deal Watch: A Closer Look At Boehringer Ingelheim’s Partnering Strategy

 
• By Joseph Haas, Vibha Ravi, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Boehringer Ingelheim GmbH is closely

Scrip

Asia Deal Watch: EpimAb Licenses Bispecific Antibody To Newly Formed Vignette

 
• By Joseph Haas, Dexter Jie Yan, Xu Hu, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Vignette Gets Rights To BCMA×CD3 Bispec